Trials / Not Yet Recruiting
Not Yet RecruitingNCT06876701
The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab | Evaluation of the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults |
Timeline
- Start date
- 2025-04-01
- Primary completion
- 2027-04-01
- Completion
- 2027-04-01
- First posted
- 2025-03-14
- Last updated
- 2025-03-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06876701. Inclusion in this directory is not an endorsement.